User login
Kim Chong, MD, Adil Daud, MD, Susana Ortiz-Urda, MD, PhD, and Sarah T. Arron, MD, PhD; for the UCSF High Risk Skin Cancer Program
Traditional chemotherapy has resulted in only a modest response, if any, for the 3 most common cutaneous malignancies of basal cell carcinoma, squamous cell carcinoma, and melanoma. Recent advances in understanding of the defects in the pathways driving tumorigenesis have changed the way that we think of these cancers and paved the way to targeted therapy for specific tumors. In this review, we will introduce the novel systemic treatments currently available for these cancers in the context of what is understood about the tumor pathogenesis. We will also introduce ongoing studies that will hopefully broaden our options for highly effective and tolerable treatment.
*For a PDF of the full article, click on the link to the left of this introduction.
Kim Chong, MD, Adil Daud, MD, Susana Ortiz-Urda, MD, PhD, and Sarah T. Arron, MD, PhD; for the UCSF High Risk Skin Cancer Program
Traditional chemotherapy has resulted in only a modest response, if any, for the 3 most common cutaneous malignancies of basal cell carcinoma, squamous cell carcinoma, and melanoma. Recent advances in understanding of the defects in the pathways driving tumorigenesis have changed the way that we think of these cancers and paved the way to targeted therapy for specific tumors. In this review, we will introduce the novel systemic treatments currently available for these cancers in the context of what is understood about the tumor pathogenesis. We will also introduce ongoing studies that will hopefully broaden our options for highly effective and tolerable treatment.
*For a PDF of the full article, click on the link to the left of this introduction.
Kim Chong, MD, Adil Daud, MD, Susana Ortiz-Urda, MD, PhD, and Sarah T. Arron, MD, PhD; for the UCSF High Risk Skin Cancer Program
Traditional chemotherapy has resulted in only a modest response, if any, for the 3 most common cutaneous malignancies of basal cell carcinoma, squamous cell carcinoma, and melanoma. Recent advances in understanding of the defects in the pathways driving tumorigenesis have changed the way that we think of these cancers and paved the way to targeted therapy for specific tumors. In this review, we will introduce the novel systemic treatments currently available for these cancers in the context of what is understood about the tumor pathogenesis. We will also introduce ongoing studies that will hopefully broaden our options for highly effective and tolerable treatment.
*For a PDF of the full article, click on the link to the left of this introduction.